Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells.

Learn More

From Promise to Therapy

Seattle Genetics is conducting clinical trials in these and other therapeutic areas:

  • Hodgkin lymphoma
  • Non-Hodgkin lymphoma
  • Urothelial cancer
  • Breast cancer

View all clinical trials

Join The Seattle Genetics Team

We are a group of passionate innovators dedicated to positively impacting the lives of those living with cancer, and we're always looking to add to our team.

Learn More

Recent News

Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2017 Financial Results on February 6, 2018 More

Seattle Genetics Highlights Leadership in Expanding Field of Antibody-Drug Conjugates (ADCs) at the 36th Annual J.P. Morgan Healthcare Conference More

FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma More

View All News

Seattle Genetics At A Glance

Year founded 1998

Global Headquarters Bothell, WA

Nasdaq SGEN

Number of Employees 1,000+

Clinical & preclinical pipeline programs 12+

ADCs in clinical trials using our technology 20+